Amryt Pharma Stock Deutsche Boerse AG

Equities

Delayed Deutsche Boerse AG Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

2021	Amryt Pharma to Delist from LSE's Main Market in January 2022	MT
2021	Amryt Pharma : Boosts FY21 Revenue Guidance Following Chiasma Purchase	MT

Duration

Period

Style

Amryt Pharma to Delist from LSE's Main Market in January 2022	21-11-22	MT
Amryt Pharma : Boosts FY21 Revenue Guidance Following Chiasma Purchase	21-09-13	MT
Amryt Pharma : Hikes FY21 Guidance As H1 Loss Narrows On Strong Growth	21-08-06	MT
Amryt Pharma : Completes Acquisition Of Chiasma	21-08-05	MT
Novacyt : CEO to Retire; Amryt Pharma Exec Named Successor	21-07-29	MT
Amryt Pharma : Sends Invitation To Shareholders To Vote For Chiasma Acquisition	21-06-28	MT
Amryt Pharma : Wins US FDA's Priority Review Status For Rare Genetic Skin Disorder Drug	21-06-03	MT
Amryt Pharma : Receives New Drug Application Status For Oleogel-S10 In US	21-06-02	MT
Amryt Pharma : Submits New Rare Disease Drug for US FDA Approval	21-03-31	MT
Amryt Pharma : Reports Encouraging Results From Familial Chylomicronaemia Syndrome Drug Trial	21-03-30	MT
Amryt Pharma : Shares Rise 5% on European Medicines Agency Progress for Skin Disorder Drug	21-03-29	MT
Amryt Pharma : Seeks to Double Leptin Deficiency Drug Myalepta's Market Share in US	21-03-23	MT
Amryt Pharma : Myalepta Receives Reimbursement Approval in France	21-03-22	MT
Amryt Pharma : Agrees Distribution of Myalepta In Canada	21-03-08	MT
Amryt Pharma : Myalepta Receives Reimbursement Approval in England, Wales	21-01-20	MT

Sector